RxDoctor Payments Data

Cynthia Wilder, MD

Internal Medicine · Dallas, TXNPI 1942213392

Payments from drug & device makers

$6,157in general payments, 2019–2025

Across 328 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$667
  • Novo Nordisk$593
  • AbbVie$539
  • GSK$481
  • Pfizer$464
  • Novartis$462
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,157 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$85,437
Medicare patients
214
Services billed
1,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$147,957
EliquisApixaban83$88,246
MounjaroTirzepatide42$54,280
MyrbetriqMirabegron29$27,284
FarxigaDapagliflozin Propanediol22$22,280
XareltoRivaroxaban13$21,523
JardianceEmpagliflozin28$21,290
LinzessLinaclotide30$19,907
JanuviaSitagliptin Phosphate14$19,700
Praluent PenAlirocumab16$15,502
TrulicityDulaglutide12$11,970
SynthroidLevothyroxine Sodium114$10,028
DapagliflozinDapagliflozin Propanediol13$6,822
PremarinEstrogens, Conjugated18$6,368
Levothyroxine Sodium236$4,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$593$147,957156 claims
PfizerEliquis, Premarin$464$94,614101 claims
Lilly USA, LLCMounjaro, Trulicity$88$66,25054 claims
AbbVieLinzess, Synthroid$539$29,934144 claims
Astellas Pharma US IncMyrbetriq$114$27,28429 claims
AstraZenecaFarxiga$165$22,28022 claims
Johnson & JohnsonXarelto$118$21,52313 claims
Boehringer IngelheimJardiance$62$21,29028 claims
MerckJanuvia$124$19,70014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →